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Abstract
Prognostic factors are used for treatment decisions in
rheumatoid arthritis (RA). High disease activity, the
early presence of erosions, and autoantibody positivity
are the most frequently used poor prognostic factors
but other features, such as functional disability,
extraarticular disease, or multibiomarkers, are also
assessed. Prognostic factors are incorporated in current
treatment recommendations for the management of
RA and are used as inclusion criteria in randomized
controlled trials. They are defined heterogeneously
and the relevance of a single or combined presence of
poor prognostic factors remains unclear. This review
summarizes the current definitions of poor prognostic
factors and their use in clinical research. Perspectives on
future research are also outlined.
Keywords: Rheumatoid arthritis, Prognostic factors,
Treatment, Outcome
Background
Prognostic factors have been established as a clinical tool
for treatment decisions in rheumatoid arthritis (RA).
When to initiate treatment with disease-modifying anti-
rheumatic drugs (DMARDs) in very early RA, treatment
intensity, including switching of therapies, and individual
treatment response are three domains where prognostic
factors are of relevance [1].
Consistently, three factors are considered to be of rele-
vance for the prognosis of RA. These are high disease
activity, positivity for rheumatoid factor (RF) and/or
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anti-citrullinated protein-peptide antibodies (ACPA), and
the early presence of structural damage [2]. Other factors
include functional disability, extraarticular disease, im-
aging markers, and novel multibiomarkers. These features
are still under investigation or do not appear uniformly in
recommendations and clinical research. Besides the type
of prognostic factors, definitions, measurements, the
relevant outcome, and the timepoint of the measured
outcome also vary among the existing studies.
This review provides an overview on the use of poor
prognostic factors in randomized controlled trials, in
cohort studies, and in treatment recommendations.
Definitions are compared and the use is described.
A PubMed search was performed to identify the publi-
cations in this review with the following search terms
used: rheumatoid arthritis, poor prognostic factors, poor
prognosis, prediction. Full-text papers published until
November 2016 were included and references were
screened for further relevant papers.
Definition of prognostic factors
Prognostic factors are used for RA diagnosis, treatment
decisions, and prognosis of disease severity. So far, there
is no uniform definition of poor prognostic factors. Fac-
tors that are used predominantly for treatment decisions
are high disease activity, the early presence of erosions,
and autoantibody positivity [3, 4]. These factors are
acknowledged to be of importance for the course of RA
[2]. Other factors that have been investigated include
disability at baseline, extraarticular disease, smoking, im-
aging markers, protein biomarkers, and genetic markers.
Disease activity
Disease activity has been assessed by serum levels of
C-reactive protein (CRP) and erythrocyte sedimentation
rate (ESR) as well as the number of tender joints (TJC)
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and swollen joints (SJC). In risk models, different cut-off
values have been used for these parameters to predict pa-
tients at risk for rapid radiographic progression (Table 1).
Heterogeneous definitions are also applied for the defin-
ition of disease activity as inclusion criteria in randomized
controlled trials (Table 2). In treatment recommendations,
high disease activity is either not further specified or
defined by validated composite scores such as the disease
activity score based on 28 joints (DAS28 > 5.1) [3–5].
Serologic factors
Autoantibody positivity can be defined as either RF-
positive, ACPA-positive, one of the two, both of them, or
a high autoantibody titer. Most commonly, poor prognosis
is assessed by RF or ACPA positivity [3, 4] but other defi-
nitions are also used (e.g., ACPA three or more times the
upper limit of normal [6] or RF >200 U/l [7], ACPA and
RF positivity [8]).
Erosions
The presence of erosions at baseline has been reported
by qualitative measure (yes/no) [7] or by the evaluation
of radiographs using the Sharp score [9]. “Typical RA
erosions” are also used for definition [10, 11].
Functional limitation
Functional limitation has rarely been investigated as a
poor prognostic marker but has been reported consist-
ently by health assessment questionnaire (HAQ) scores
[12, 13]. In the American College of Rheumatology
(ACR) Recommendations for the use of DMARDs and
Biologics in the treatment of RA it is stated that
functional limitation could also be reported by similar
valid tools [4].
Extraarticular disease
Extraarticular disease appears as a poor prognostic fea-
ture in the ACR recommendations only. The importance
of extraarticular RA features is that they reflect severe
disease, more often seen in past and longstanding
disease. They should be kept in mind even though no
validation studies have referenced extraarticular disease
as a prognostic factor [4].
Smoking
Smoking is known to be associated with the development
of RA and with treatment response [14] but the impact on
clinical or radiologic outcomes has not been clarified. In a
risk model from the SWEFOT cohort, current smoking
was reported to be a strong independent predictor of
radiographic progression [15]. In the ESPOIR cohort,
smoking was not predictive of rapid radiologic progression
[10]. In any way, smoking as a patient habit is not consid-
ered in treatment recommendations [3, 4].
Treatment response
Results from an Italian early arthritis cohort provided
evidence that in early RA, less than 12 weeks’ disease
duration at the time of first treatment and DMARD ini-
tiation within 3 months were the main predictors of
DAS28 remission [16]. In contrast to the risk models,
not structural damage but remission was the targeted
outcome here. Analyses from the PREMIER and
TEMPO trials already demonstrated that early treatment
response predicted low disease activity [17, 18].
Biomarkers
Various biomarkers have already been established as
prognostic factors. Autoantibodies and inflammatory
Table 1 Identification of poor prognostic factors in randomized trials and observational cohort studies
Poor prognostic factor Outcome Study type References




[7, 9, 11, 15]
[12, 42]
Increased MBDA Radiographic progression RCT, cohort [21, 23]






Presence of erosions Radiographic progression RCT, cohort [9, 11, 14, 32]






Smoking Radiographic progression RCT [15]
Delayed diagnosis/treatment initiation Absence of remission Cohort [16]
Ultrasound Doppler activity Radiographic progression
Absence of remission
Cohort [24, 25]
MRI bone edema Radiographic progression RCT, cohort [26–28]
Genetic predisposition (relatedness) Radiographic damage Cohort [29]
ACPA anti-citrullinated protein-peptide antibodies, HAQ Health Assessment Questionnaire, MBDA multibiomarker disease activity score, MRI magnetic resonance
imaging, DAS28 disease activity score of 28 joints, RCT randomized controlled trial, RF rheumatoid factor
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markers as well as joint counts are validated factors that
are used in routine care to assess the severity and course
of RA. As the inflammatory markers ESR and CRP are
not specific to RA, they cannot be expected to be highly
predictive. Therefore, novel mechanistic biomarkers that
are directly involved in the disease pathogenesis are
being increasingly investigated [19].
Protein biomarkers
The multibiomarker disease activity (MBDA) score is an
RA disease activity measure based on serum concen-
trations of 12 protein biomarkers that include tumor
necrosis factor receptor I (TNF-RI), interleukin 6 (IL-6),
vascular cell adhesion molecule 1 (VCAM-1), epidermal
growth factor (EGF), vascular endothelial growth factor
A (VEGF-A), cartilage glycoprotein 39 (YKL40), matrix
metalloproteinase 1 (MMP1), MMP3, serum amyloid A
(SAA), leptin, and resistin [20]. The MBDA blood test
has been validated to quantify RA disease activity on a
score between 1 and 100, >44 meaning high disease ac-
tivity [21]. The MBDA has been assessed in cohort valid-
ation studies to predict the patient risk for radiologic
progression [22, 23]. In the SWEFOT trial, patients with
persistently high MBDA scores (>44) had the highest
risk for radiologic progression during a 2-year follow-up
[23]. The association of increased MBDA scores with
radiologic progression was also found in one-year data
from the Leiden early arthritis cohort [22]. The MBDA
score may become a potential prognostic tool but,
like imaging biomarkers, it is not incorporated in
routine care.
Imaging biomarkers
Ultrasound and magnetic resonance imaging (MRI) en-
able the assessment of disease activity and structural
damage by the visualization of anatomical and structural
changes [17]. Several studies indicated the ability of
power Doppler ultrasound to predict disease activity and
structural damage [24, 25]. Bone edema in MRI was
predictive for radiologic progression in randomized
controlled trial (RCT) and cohort studies [26–28]. The
contribution of imaging markers to the prediction of a
poor prognosis has not been confirmed in prediction
models and it remains a marker that can only be imple-
mented in centers with appropriate imaging facilities.
The Italian Society of rheumatology has taken these re-
sults into account and added active synovitis assessed by
power Doppler signals as a prognostic feature in their
treatment recommendations for the use of biologic
therapy in RA [5].
Genetic biomarkers
A genetic predisposition not only for the development of
RA but also for disease severity is indicated by a
Table 2 Poor prognostic factors used as inclusion criteria in randomized controlled trials
Trial Inclusion criteria Primary endpoint Secondary endpoints
AGREE [45] RA (1987) ≤2 years, MTX-naïve
Poor prognosis: RF/ACPA-positive, SJC ≥10,
TJC ≥12, CRP ≥4.5 mg/l, erosions
Remission (DAS28-CRP <2.6)




TEAR [42] RA (1987) <3 years, biologic DMARD-naïve
Poor prognosis: RF/ACPA positive or
radiologic erosions
Active: SJC ≥4, TJC ≥4 (28 joints),
DAS28-ESR >3.2
DAS28-ESR at week 48 and 102 ACR response
Modified HAQ
Joint damage
C-EARLY [40] RA (2010) ≤1 year, DMARD-naïve
poor prognosis (RF/ACPA-positive)
Active RA: SJC ≥4, TJC ≥4, DAS28-ESR >3.2,
ESR ≥28 or CRP ≥10 mg/l
Sustained remission (DAS28-ESR <2.6) or low
disease activity (<3.2) at week 40 and 52
ACR response HAQ-DI
TSS (change from baseline)
At week 52
C-OPERA [6] RA (2010) ≤1 year, MTX-naïve
Poor prognosis (ACPA ≥3× upper limit of
normal and RF-positive and/or erosions
Active RA: DAS28-ESR ≥3.2
Non-progression (defined: mTSS ≤0.5
change from baseline to 12 months)
SDAI, Boolean and DAS28-ESR
HAQ-DI
ACR response
FUNCTION [41] RA (1987) ≤2 years, MTX-naïve
Poor prognosis: RF/ACPA-positive or
radiologic erosions
Active RA: DAS28-ESR >3.2, SJC ≥4 (66 joints),
TJC ≥6 (68 joints), ESR ≥28 or CRP ≥10 mg/l
Remission (DAS28-ESR <2.6 at week 24 ACR response
Modified TSS
SF-36
CareRA [46] RA (1987) ≤1 year, DMARD-naïve
Lack of poor prognosis: no erosions,
DAS ≤3.2, seronegative
Remission (DAS28-CRP ≤3.2) at week 16 EULAR response
HAQ response
Cumulative disease activity
ACPA anti-citrullinated protein-peptide antibodies, ACR American College of Rheumatology, CRP C-reactive protein, ESR erythrocyte sedimentation rate, EULAR European
League Against Rheumatism, HAQ-DI Health Assessment Questionnaire Damage Index, HRQoL health-related quality of life, MTX methotrexate, DAS disease activity score,
DMARD disease-modifying antirheumatic drug, TSS Total Sharp Score, RA rheumatoid arthritis, RF rheumatoid factor, SDAI Simple Disease Activity Index, SF-36 Short
Form-36, SJC swollen joint count, TJC tender joint count
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population-based study of Knevel et al. [29]. In a cohort
of 325 Islandic patients, relatedness was significantly pre-
dictive of differences in the rate of joint destruction [30].
Independent of heterogeneous definitions, the validity
of all prognostic factors depends on the outcome of
interest that differs in the available literature.
Definition of outcomes
Joint damage, remission, and functional limitation are
the main outcomes predicted by poor prognostic factors.
Joint damage is by far the most often used outcome
parameter. It is mostly defined by rapid radiologic pro-
gression, meaning an increase in the van der Heide
Sharp Score of five or more points within the first year
after treatment initiation [31]. Sometimes it is also
defined on a qualitative measure as the (new) presence
of erosions (yes/no).
Remission is mostly defined by the DAS28 using either
DAS28-erythrocyte sedimentation rate (ESR) <2.6 [12, 16]
or DAS-CRP <2.6 [29]. In the careRA trial, remission was
defined as DAS28-CRP <3.2 [30]. Other standard
definitions of remission according to the Clinical Disease
Activity Index (CDAI), the Simplified Disease Activity
Index (SDAI), or the Routine Assessment of Patient Index
Data (RAPID-3) are also considered in the ACR recom-
mendations [4].
Functional limitation is usually assessed with the
HAQ. HAQ values ≥1.5 were reported by Gremese et al.
as moderate disability outcome after one year of therapy
[16]. HAQ scores ≥1 after three months were used in
the BeSt trial for short-term functional disability [13].
Validation of prognostic factors in RCT and cohort
studies
Risk models
Various risk matrices have been developed to identify pa-
tients at risk for rapid radiologic progression [7, 9, 15, 32].
These prediction models are matrix models and all consist
of at least two matrices to consider the different treatment
strategies in the original trials they are derived from. They
are discussed in detail in a review by van der Helm-van
Mil [1]. These matrices provide estimates of the prob-
ability of having rapid radiologic progression at one year if
one predictor or a combination of predictors are present.
All but one risk model were developed in patients derived
from RCTs and showed only poor discriminative
ability in validation cohorts representative of a wider
RA population.
Validation studies
Analyses from the BeSt trial and from the ESPOIR and
BRASS cohorts showed that risk matrices only moder-
ately performed in predicting radiologic progression
[8, 10, 33]. In the BEST study, patients with or without
poor prognostic factors benefitted from combination ther-
apy. The clinical outcome was rather related to a fast
treatment response than to initial prognosis.
Current use of poor prognostic factors
Poor prognostic factors in treatment recommendations
The European League Against Rheumatism (EULAR) has
included the presence of poor prognostic factors as a
decision-criterion at the time of the first conventional syn-
thetic (cs)DMARD failure. According to Recommendation
8, the change to another csDMARD strategy should be
considered in the absence of poor prognostic factors, and
addition of a bDMARD should be considered when poor
prognostic factors are present [3]. A high disease activity
state, autoantibody positivity (RF and/or ACPA), and the
early presence of joint damage are listed as poor prognos-
tic factors. In their 2012 update of the recommendations
for the use of DMARDs in RA treatment, the ACR uses
disease activity and prognostic features as separate
parameters. Besides autoantibody positivity and erosions,
functional limitation and extraarticular disease are also
considered as poor prognostic features [4].
In the EULAR recommendations, the poor prognostic
factors are not further specified regarding a single or
combined presence, the thresholds, or the measurement
of these criteria. The ACR categorizes low, moderate, or
high disease activity as per validated common scales, or
the treating clinician’s formal assessment [4]. Patients
are then categorized based on presence or absence of
one or more of the following poor prognostic features:
functional limitation (e.g., HAQ score or similar valid
tools); extra-articular disease (e.g., presence of rheuma-
toid nodules, RA vasculitis, Felty’s syndrome); RF or
ACPA antibodies; bony erosions on radiographs. Treat-
ment recommendations depend on the presence of low,
moderate, or high disease activity and on the presence of
poor prognostic features. In addition, both are consid-
ered differently in patients with early or established RA
(Table 3).
The target of RA treatment, addressed in both recom-
mendations, is low disease activity or remission. The
references used in the EULAR recommendations refer
to risk models from the ASPIRE and the BeSt trials
where rapid radiologic progression was the main out-
come [7, 9]. In the ACR recommendations, references
are given for autoantibody positivity and erosions only.
National recommendations are predominantly based
on the international recommendations [34–37]. But
several aspects regarding prognostic factors vary. The
French recommendations give advice to consider high
RF/ACPA titers and the progression of radiologic dam-
age [35]. In the Italian recommendations, the persistence
of more than one swollen joint and active synovitis
assessed with power Doppler signals are also included as
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prognostic features that allow for bDMARD initiation [5].
The British Society of Rheumatology has the only recom-
mendation that does not include poor prognostic factors
as decision-criteria as they already have a strict inclusion
of patients presenting twice with DAS28 values above 5.1
[38]. The 2015 ACR Guideline for the treatment of
rheumatoid arthritis are also only based on patients` dis-
ease activity level without including additional poor prog-
nostic markers. Besides methodical reasons, the panel
agreed that prognosis was already largely captured by
disease activity and information regarding prognosis was
unlikely to further contribute to decision-making [39].
In summary, the consideration of poor prognostic fac-
tors as decision-criteria is highly important since current
treatment recommendations allow for treatment intensi-
fication with bDMARDs earlier in patients with than
without poor prognostic factors. However, there is
remaining heterogeneity in the definition of poor prog-
nostic factors that needs further clarification.
Poor prognostic factors in randomized controlled trials
Although the treatment recommendations are very consist-
ent in suggesting bDMARD therapy in patients with poor
prognostic factors at the time of the first DMARD failure,
poor prognostic factors are used as inclusion criteria in
RCTs for early treatment with bDMARDs in patients with
csDMARD-naive RA [6, 31, 40, 41]. In the TEAR trial,
bDMARD-naïve patients with a disease duration shorter
than three years with poor prognosis were included [42].
RA diagnosis criteria (ACR of 1987 or ACR/EULAR 2010),
disease duration, and features of poor prognosis are defined
heterogeneously. In the careRA trial, the lack of poor prog-
nostic factors was defined as inclusion criteria (Table 2).
The primary outcome in these RCTs is remission with dif-
ferent cut-offs and timepoints and secondary outcomes in-
clude non-progression or joint damage.
Stratification for prognosis
No rating is obtained in the current recommendations to
precisely define patients with or without poor prognosis. The
importance of single or combined presence is not assessed.
In a post hoc analysis from the BeSt trial, two methods were
applied [8]. Poor prognosis was, firstly, defined as the pres-
ence of at least three out of four poor prognostic factors:
DAS ≥3.7, SJC ≥10, erosions ≥4, and both RF- and ACPA-
positive. With this assessment, 46% of the cohort were
assessed as having a poor prognosis. However, of the 54%
without poor prognosis, more than 60% had erosive disease
and more than 40% were either ACPA- or RF-positive.
Secondly, Markusse et al. [8] used a cut-off of 50% of
all patients at risk for rapid radiographic progression
from the BeSt matrix for initial monotherapy to
Table 3 Treatment recommendations with poor prognostic factors as decision-criteria
RA state Poor prognostic factors Presence allows for Treatment target
EULAR [3] RA, first DMARD failure High disease activity, RF/ACPA positivity,
early presence of joint damage
bDMARDs Low disease activity or
remission
ACR [4] Early RA <6 months Moderate disease activity + ≥1 of
functional limitation, extraarticular
disease, RF/ACPA positivity, erosions
csDMARD combination
High disease activity + one or more of
functional limitation, extra-articular
disease, RF/ACPA positivity, erosions
bDMARD or csDMARD
combination
Established RA (≥6 months or
1987 ACR criteria)
LDA+one or more of functional limitation,
extraarticular disease, RF/ACPA positivity,
erosions or at least moderate disease activity
csDMARD combination,
bDMARD at 3 months
Italy [5] RA, DMARD failure 1. High disease activity (DAS28 > 5.1 for
≥1 months
2. Moderate disease activity (DAS >3.2) +
ACPA/RF positive and elevated CRP or
ESR, persistence of one or more swollen
joint, bone erosions on X-rays, active
synovitis with power Doppler signal
3. New erosions
bDMARD
France [35] RA, DMARD failure Existence or progression of structural
damage, high clinical and/or laboratory
activity, high RF/ACPA titers
bDMARD
Germany [34] RA, 1st DMARD failure High disease activity, RF/ACPA positivity,
early presence of joint damage
bDMARD
Canada [36] RA Not further specified Initial csDMARD combination
ACPA anti-citrullinated protein-peptide antibodies, ACR American College of Rheumatology, CRP C-reactive protein, ESR erythrocyte sedimentation rate,
EULAR European League Against Rheumatism, DAS disease activity score, bDMARD biologic disease-modifying antirheumatic drug, csDMARD conventional synthetic
disease-modifying antirheumatic drug, RA rheumatoid arthritis, RF rheumatoid factor
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distinguish poor prognosis and non-poor prognosis
patients. These approaches underline that there is no
standardized stratification for patients with a “poor
prognosis”, whatever that means.
Value of prognostic factors and perspectives
The review of the current data on poor prognostic
markers reveals that they have been derived from predic-
tion models that were developed to predict rapid radio-
logic progression in patients with early RA or with less
than three years disease duration. During the past
decade, the development of structural changes in RA
has declined and 70% of patients on methotrexate are
reported to be without structural damage [10]. Treat-
ment targets have shifted towards achieving remission or
at least low disease activity [3, 4], but for these targets,
poor prognostic factors are not validated. Future re-
search questions should focus on the following points:
– The definition of poor prognostic markers depends
on the targeted outcome, the methods of
measurement, and the cut-off values. These
heterogeneous data need to be harmonized when
poor prognostic markers are incorporated in
treatment recommendations.
– What is the target of prognostic markers? Do we
need to validate prognostic factors for remission or
low disease activity rather than for structural
damage? Or do we need a combined target that
includes the absence of erosions, absence of disease
activity, and the preservation of functional status?
– Can high disease activity at baseline be regarded as a
poor prognostic factor or is it rather active disease over
time? Time-integrated DAS28-ESR values during the
first year post baseline were assessed by Koga et al.
[11]. Rapid progression was the outcome and for this
target, time-integrated DAS28 was not predictive.
– The incorporation of novel potential prognostic
factors into risk models is requested by van der
Helm-van Mil [1]. Multibiomarkers, imaging
markers, and patient-reported outcomes are
currently under investigation and it will be challenging
to combine these factors into one predictive model.
– The frequency of poor prognostic markers in
representative RA cohorts has not been assessed in
detail. There is a specific lack of information on the
prevalence of single or combined prognostic markers
and their relevance. It remains unclear whether
patients with autoantibodies and erosions or only one
of those markers have different outcomes regarding
remission, function, or joint damage [2].
– Should seronegative RA be treated differently? At
the same level of inflammation, ACPA-negative
patients have less joint damage and a lower
probability of damage in newly affected joints than
ACPA-positive patients. De Punder et al. [43]
proposed that low disease activity might be a
sufficiently strict treatment target for ACPA-negative
patients to prevent progression of joint damage. But it
is not evident whether this also applies for remission
and functional preservation.
Conclusions
The use of poor prognostic factors varies among recom-
mendations, clinical trials, and cohort studies. The rele-
vance of poor prognostic factors for the outcome of RA
remains challenging as treatment strategies always inter-
fere as confounders. Future research perspectives are to
assess the prevalence of prognostic factors in cohort
studies, to assess the relevance of different combinations
of prognostic factors in randomized trials, and to include
biomarkers and early treatment response as prognostic
factors in the development of new risk models.
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